ATGAM

This brand name is authorized in Canada, Estonia, Hong Kong, Ireland, Japan, New Zealand, Romania, Singapore, United Kingdom, United States, South Africa

Active ingredients

The drug ATGAM contains one active pharmaceutical ingredient (API):

1	Antithymocyte immunoglobulin UNII 475247QF1Z - EQUINE THYMOCYTE IMMUNE GLOBULIN
	Antithymocyte immunoglobulin is a selective immunosuppressive agent mostly acting on T lymphocytes. Antithymocyte immunoglobulin is used for the prevention and treatment of graft rejection after solid organ transplantation, usually in combination with other immunosuppressive drugs.
	Read more about Antithymocyte immunoglobulin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ATGAM Concentrate for solution for infusion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AA03	Antilymphocyte immunoglobulin (horse)	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02234470
EE	Ravimiamet	1717231
GB	Medicines & Healthcare Products Regulatory Agency	321506
HK	Department of Health Drug Office	20962
JP	医薬品医療機器総合機構	63994A8A1028
NZ	Medicines and Medical Devices Safety Authority	4179
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68563001
SG	Health Sciences Authority	01490P
US	FDA, National Drug Code	0009-7224
ZA	Health Products Regulatory Authority	T/30.4/717